• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

Roche, Shionogi aim for new standard of care flu treatment with Xofluza

Oct. 25, 2018
By Marie Powers
Two months to the day before its Dec. 24 PDUFA date, Xofluza (baloxavir marboxil, previously S-033188, RG-6152), gained a nod from the FDA to treat acute uncomplicated influenza in individuals 12 and older who became symptomatic within the previous 48 hours.
Read More

Pfizer lures Bain to brain in CNS-focused startup Cerevel

Oct. 24, 2018
By Marie Powers
Maybe those Pfizer Inc. neuroscience assets weren't so lackluster after all. The New York-based pharma and deep-pocketed partner Bain Capital LP placed a portfolio of eight disclosed preclinical and clinical central nervous system (CNS) candidates into the newco Cerevel Therapeutics LLC and backed them with $350 million in committed capital from funds associated with Bain Capital Private Equity and Bain Capital Life Sciences
Read More

CF you can catch me: Proteostasis makes stunning run on phase I data

Oct. 19, 2018
By Marie Powers
Shares of Proteostasis Therapeutics Inc. (NASDAQ:PTI) roared Thursday, spiking to an 18-month high of $10.38, following an update on three cohorts covering 21 patients from the company's ongoing phase I study of combination doublet, PTI-801/PTI-808, in individuals with cystic fibrosis (CF). The stock closed at $10.35 for a gain of $8.46, or 447.6 percent. Volume of nearly 92.6 million shares was some 580 times the company's three-month moving average.
Read More

Afferent investors come back for seconds with $54.5M series A at Curasen

Oct. 18, 2018
By Marie Powers
New Leaf Venture Partners, which led the $54.5 million series A by startup Curasen Therapeutics Inc., got in on the ground floor of a previous venture by company co-founders Anthony Ford, named CEO, and Kathleen Sereda Glaub, executive chair. Their former effort, Afferent Pharmaceuticals Inc., went to Merck & Co. Inc. in a 2016 buyout worth up to $1.25 billion for the orally administered P2X3 antagonist AF-219 to treat refractory chronic cough and idiopathic pulmonary fibrosis with cough. 
Read More

Immunicum lines up institutional investors for ilixadencel directed issue

Oct. 17, 2018
By Marie Powers
Immunicum AB raised SEK351 million (US$39.5 million) through a directed issue of approximately SEK178 million to institutional investors and a fully guaranteed rights issue of approximately SEK173 million to existing holders of the company's shares, which trade on Nasdaq Stockholm. The twofold goal was to bring Swedish institutions into the company's fold and to secure sufficient funding to move lead candidate ilixadencel – a vaccine based on allogeneic dendritic cells from healthy individuals that's designed to prime the immune system against solid tumors – into phase Ib/II studies in head and neck, non-small-cell lung (NSCLC) and stomach cancers.
Read More

PDQ for SQZ as Roche sweetens cell therapy partnership for potential $1.375B-plus

Oct. 16, 2018
By Marie Powers
Less than three years after inking a potential $500 million cell therapy partnership with SQZ Biotechnologies Co., Roche Holding Co. is going back for seconds in an expanded deal that could more than triple the economics. SQZ is set to receive $125 million in up-front and near-term milestones and could earn up to $250 million in clinical, regulatory and sales milestones for each product that emerges from the expanded collaboration. In addition, the Watertown, Mass.-based company may receive development milestone payments exceeding $1 billion. Moreover, the five-year-old biotech could share commercial rights with Roche, of Basel, Switzerland, for certain approved products.
Read More

AADPAC members endorse FDA review, offer broad support to Dsuvia

Oct. 15, 2018
By Marie Powers
Members of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) on Friday seemed to have more questions about Dsuvia for Acelrx Pharmaceuticals Inc. than did FDA reviewers, who followed up their mostly positive briefing document by observing the company had submitted "the kinds of information" needed to resolve last year's complete response letter (CRL) for the opioid analgesic.
Read More

All aboard Allogene in biopharma's biggest YTD U.S. IPO

Oct. 12, 2018
By Marie Powers
Not unlike the zeal of trainspotters, the allure of chimeric antigen receptor T cell (CAR T) therapy continues to attract devoted fans. And biopharma investors clearly expect the former management team at Kite Pharma Inc. to keep that train rolling down the track.
Read More

Roche piggybacks on Huntington, taps Ionis for 'complementary' partnership

Oct. 11, 2018
By Marie Powers
Roche Holding AG issued a vote of confidence in partner Ionis Pharmaceuticals Inc. by tapping the Carlsbad, Calif.-based company for a second alliance, focused on the treatment of complement-mediated diseases. The companies will collaborate on the development of IONIS-FB-LRx, targeting factor B (FB), in a broad range of diseases, beginning with geographic atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD).
Read More

RNA-regulated targeting takes Rgenix to $40M series C, bigger trials

Oct. 10, 2018
By Marie Powers
Rgenix Inc. tapped existing investors Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments LLC and the Partnership Fund for New York City's Innovate NY Fund for its $40 million series C, but the round was led by new investor Lepu Medical Technology Co. Ltd., of Beijing, a publicly traded medical device maker that is expanding its footprint in therapeutic development – immuno-oncology (I-O), in particular. Oceanpine Capital and Wuxi Apptec's Corporate Venture Fund also joined the syndicate.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe